30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

2Q14 Revenue: SpineGuard

(1H14 sales)

€2.1MM (~US $2.8MM), -6%

  • Growth affected by unfavorable U.S. markets (U.S. sales account for 50% of units sold and 71% of revenue)
  • Continuing R&D focus on potentially disruptive Smart Screw technology, running ahead of development plan
  • To date, PediGuard adopted by >20 U.S. spine surgery teaching hospitals